MINUTES OF MEETING - December 6-7 
10 
(b) reccrmend to the RAC procedures for continued 
monitoring of these experiments. 
(3) That experiments with the Foot and Mouth Diesease clones at 
Genentech be carried out at P3 + EK1 or P2 + EK2 containment; 
(4) Stage IV experiments (isolation of clones from other FMD 
type viruses) shall also be examined by the Working Group 
before removal of clones from Plum Island, 
or, alternatively 
(4') Stage IV experiments shall not be begun before review of 
results of Stages I-III by the RAC. 
Dr. Gottesman moved Part 1 of her motion and Mr. Thornton seconded 
the motion. The RAC recommended approval of Part 1 of the motion 
by a vote of 17 in favor, none opposed, with one abstention. 
Dr. Gottesman discussed Part 2 of her motion. Dr. Young suggested 
a preamble to Part 2 of the motion; 
"While the RAC approves the entire project in principle, 
it is recognized that data from the first phase must be 
evaluated prior to removal of any clones from Plum Island. 
Accordingly. ..." 
Dr. Gottesman accepted this amendment. 
Dr. Zaitlin said he thought the sense of the discussion was that 
the clones should not contain collectively as well as individually 
the complete genome. Dr. Gottesman agreed and modified that 
section of the motion bo read; 
"The collection of clones to be approved for removal 
from Plum Island shall not contain among them, 
collectively or individually, the full genome of 
the Foot and Mouth Disease Virus." 
Dr. Harris said that she was strongly predisposed toward 
alternative 2a' of Dr. Gottesman's motion. Dr. Baltimore 
felt that the RAC should not constantly interpose itself in the 
process and engender long delays. He favored alterative 2a. 
Dr. Goldstein said that the RAC by passing the first part of 
the motion has already given a strong go-ahead, but that it has 
a responsibility to oversee the project. 
[ 403 ] 
